專家委員會:使用復星及BioNTech疫苗益處多於風險 會將建議交予食衛局考慮
2019冠狀病毒病疫苗顧問專家委員會召集人劉澤星於記者會上指,復星及德國藥廠BioNTech(BNTX.US)的mRNA疫苗將於2月尾供港,委員會參考多項因素後認為在現時香港的疫情下,建議認可使用復星及BioNTech的疫苗的益處多於其風險,會將建議交予食衛局考慮,亦會將專業建議向公眾公開,並將有關文件上載在食衛局網頁供公眾參考。
他指出專家委員會重視接種疫苗後出現不良反應及監測,衛生署已成立新的委員會,專家將會就每宗與疫苗相關的不良反應及臨床評估等即時進行審核,而委員會成員由大學醫學院及醫管局專科醫生擔任。
委員會強調會要求復星更新臨床數據、品質證明文件等,如顧問認為接種疫苗會令公眾風險大於利益,會建議食衛局作出適切跟進行動,包括是建議取消有關認可。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.